Cancer Patients Are Turning to Chatbots: Nurses Warn the Evidence Is Not Ready

When a cancer diagnosis arrives, the questions arrive with it. What does this stage mean? Which treatment has the best evidence behind it? How do I tell my family? For decades, patients and their caregivers hunted for answers in waiting rooms, pamphlets, and late-night internet searches. Now, a growing number of them are asking a chatbot instead, and a new exchange in the journal Supportive Care in Cancer shows why oncology researchers are paying close attention to that shift, and why some of them are urging caution before the medical community celebrates it.

The exchange centers on a cross-sectional study by Ismayilov and colleagues, published in September 2026, that surveyed individuals with cancer and their caregivers about their awareness of, attitudes toward, and experiences with generative artificial intelligence tools. The study appeared in Supportive Care in Cancer, a Springer journal devoted to the supportive dimensions of cancer treatment, and it arrived at a moment when large language models have moved from research curiosities to everyday consumer products. The original research team set out to map how this population, one of the most information-hungry in all of medicine, actually encounters and uses these tools in real life.

That mapping matters because the population in question is uniquely vulnerable to both the promise and the peril of generative AI. People living with cancer and the family members who care for them experience elevated rates of anxiety and depression across the illness trajectory, a pattern documented repeatedly in the psycho-oncology literature, including work showing that disease stage predicts post-diagnosis anxiety and depression only in some cancer types, and studies linking illness perceptions to psychological distress in lung and breast cancer patients. Distress drives information-seeking, and information-seeking now increasingly means conversing with a model that can produce fluent, confident, and occasionally wrong answers in seconds.

Into this landscape comes a correspondence from a team of Japanese nursing researchers led by Kohei Kajiwara of Shimonoseki City University, with Jun Kako of Mie University, Masamitsu Kobayashi of Toho University, Maki Kanaoka of Shimonoseki City University, and Makoto Yamanaka of Aichi Medical University. Their comment, published on 14 October 2026 as article 1098 in volume 34 of the journal, engages directly with the findings and the interpretation of the original cross-sectional study. All five authors are nurses or nurse scientists by training, several holding the oncology certified nurse specialist credential, a Japanese advanced practice qualification that signals deep clinical experience with cancer care. That clinical grounding shapes the perspective they bring to the debate.

The correspondence is more than a polite academic footnote. Comments of this kind are where the fine print of a study gets interrogated: how the sample was recruited, who might have been left out, what the survey questions could and could not capture, and how far the conclusions can reasonably travel. In this case, the commenters bring to bear their own body of prior work, including a rapid review published in JMA Journal in 2025 on artificial intelligence in nursing support for families. That review examined how AI technologies are being deployed to help family caregivers, a group the original study also placed at the center of its inquiry, and it forms part of the intellectual scaffolding behind the comment.

One of the most technically interesting threads running through the exchange concerns empathy. A systematic review by Sorin and colleagues published in the Journal of Medical Internet Research in 2024 examined whether large language models can be empathetic, compiling evidence on how these systems perform when users bring them emotional distress. The question is not trivial for cancer care. Caregivers of patients with head and neck cancer, for example, have been shown in prior research to perceive quality of life differently from the patients themselves, creating a gap in understanding that supportive care services try to bridge. If a chatbot offers a form of simulated empathy at three in the morning when no clinician is available, does that help, harm, or merely substitute for human connection? The reviewers found that the evidence base is still maturing, and the Japanese commenters lean on that uncertainty in their reading of the new survey data.

The technical architecture of generative AI explains much of this caution. Large language models generate responses by predicting likely text sequences based on patterns learned from vast training corpora. They do not consult a verified medical database, they do not know when their training data went stale, and they can produce outputs that are fluent and authoritative in tone while being factually incorrect, a phenomenon researchers call hallucination. For a patient weighing treatment options or interpreting a pathology report, the difference between a well-sourced answer and a confident fabrication can carry real clinical consequences. Cross-sectional surveys can reveal how often people reach for these tools and how they feel about them, but they cannot, by design, reveal how often the tools steer those people wrong.

There is also a structural problem with surveying awareness and attitudes in this population that the correspondence implicitly highlights. People who respond to surveys about AI are, almost by definition, people comfortable enough with the technology to have an opinion. Those with lower digital literacy, older patients, those without reliable internet access, and those whose illness leaves little energy for questionnaires are systematically underrepresented. Yet these are precisely the groups whose information needs in cancer care are often greatest. Any cross-sectional snapshot of AI use among patients and caregivers must be read with that selection effect in mind, and the commenters’ clinical experience with diverse patient populations gives them a vantage point on who the survey might have missed.

The timing of the exchange is significant in its own right. The original study was published on 7 September 2026, the comment was received on 11 September, accepted on 8 October, and published on 14 October, a turnaround of barely five weeks. That speed reflects how urgently the supportive care community wants to understand the collision between consumer AI and cancer care. The commenters declared no competing interests and received no external funding for their manuscript, and they reported that no datasets were generated or analyzed in the comment itself, marking it as a scholarly response rather than a new empirical study.

What emerges from the exchange is a picture of a field trying to keep pace with its own patients. The original survey by Ismayilov and colleagues provides a valuable baseline: it documents that individuals with cancer and their caregivers are aware of generative AI, that they hold measurable attitudes toward it, and that some of them are already using it in the course of living with the disease. The Japanese nursing team’s comment insists that this baseline be interpreted through the lens of clinical reality, where psychological distress shapes information behavior, where caregiver and patient perceptions diverge, where the empathetic capacities of language models remain scientifically unsettled, and where the evidence for AI supporting families is still being assembled. Neither document settles the question. Together, they sketch the research agenda that will: longitudinal studies tracking what patients actually ask chatbots, validation studies measuring how often the answers hold up against clinical evidence, and interventions that pair the accessibility of AI with the safeguards of professional oncology care. Until those studies arrive, the message from the nurses of Shimonoseki, Tsu, Ota, and Nagakute is a measured one: the enthusiasm is understandable, the adoption is already happening, but the evidence has not yet caught up with the enthusiasm, and in cancer care, that gap is exactly where patients can get hurt.

Subject of Research: Use of generative artificial intelligence tools by individuals with cancer and their caregivers

Article Title: Comment on: “The use of generative artificial intelligence tools among individuals with cancer and their caregivers: a cross‑sectional study of awareness, attitudes, and experiences”

Article References: Comment on: “The use of generative artificial intelligence tools among individuals with cancer and their caregivers: a cross‑sectional study of awareness, attitudes, and experiences”. (n.d.). https://doi.org/10.1007/s00520-026-11345-y

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11345-y

Keywords: generative AI, cancer, caregivers, supportive care, large language models, oncology nursing, patient education, digital health, empathy, cross-sectional study, health information, artificial intelligence